RT Journal Article
SR Electronic
T1 Maintenance Rucaparib Controls Some Pancreatic Cancers
JF Cancer Discovery
JO Cancer Discov
FD American Association for Cancer Research
SP OF4
OP OF4
DO 10.1158/2159-8290.CD-NB2019-043
VO 9
IS 6
YR 2019
UL http://cancerdiscovery.aacrjournals.org/content/9/6/OF4.abstract
AB In an interim analysis, the targeted PARP inhibitor rucaparib showed encouraging signs of disease control when used as a maintenance therapy for patients with platinum-sensitive advanced pancreatic cancer and a pathogenic mutation in BRCA1, BRCA2, or PALB2.